Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
SVRA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
businesswire.com
8 hours ago
prnewswire.com
10 hours ago
prnewswire.com
10 hours ago
prnewswire.com
10 hours ago
businesswire.com
16 hours ago
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-0.10
vs -0.07
Q4.23
N/A
-0.09
vs -0.07
Q1.24
N/A
-0.11
vs -0.07
Q2.24
N/A
-0.12
vs -0.07
Q3.24
N/A
-0.11
vs -0.10
Q4.24
N/A
-0.13
vs -0.09
Q1.25
N/A
-0.12
vs -0.11
Q2.25
N/A
-0.14
vs -0.12
Q3.25
N/A
-0.13
vs -0.11
Q4.25
N/A
-0.12
vs -0.13
Sales Growth
YoY
Current
Estimates
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
NA vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
NA
272K vs NA
Q1.25
NA
NA vs NA
Q2.25
NA
NA vs NA
Return on Equity
QoQ
Q1.23
-8%
-0.08
vs -0.10
Q2.23
-13%
-0.13
vs -0.08
Q3.23
-11%
-0.11
vs -0.13
Q4.23
-11%
-0.11
vs -0.11
Q1.24
-17%
-0.17
vs -0.11
Q2.24
-22%
-0.22
vs -0.17
Q3.24
-12%
-0.12
vs -0.22
Q4.24
-17%
-0.17
vs -0.12
Q1.25
-18%
-0.18
vs -0.17
Q2.25
-25%
-0.25
vs -0.18
Institutionnal Ownership
QoQ
Q4.22
55
55
vs 52
6%
Q1.23
71
71
vs 55
29%
Q2.23
78
78
vs 71
10%
Q3.23
86
86
vs 78
10%
Q4.23
99
99
vs 86
15%
Q1.24
124
124
vs 99
25%
Q2.24
145
145
vs 124
17%
Q3.24
128
128
vs 145
-12%
Q4.24
136
136
vs 128
6%
Q1.25
137
137
vs 136
1%
Quote Panel
Key Metrics
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
NASDAQ
Unprofitable
Unprofitable
0.01 ( 0.33%)
Relative Strenght
18
Volume Buzz
-34%
Earning Acce
No
Dist 52w H.
35%Relative Strength
SVRA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
2026-Revenue
-246%2026-EPS
118%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
5.00(63.93%)
Number of analyst
1
Last analyst upgrade/downgrade
H.C. Wainwright
upgradePrevious: Neutral
2025-08-15
Now: Buy
H.C. Wainwright
downgradePrevious: Buy
2025-05-29
Now: Neutral
Piper Sandler
initialisePrevious: Not converted
2021-03-16
Now: Overweight
Oppenheimer
initialisePrevious: Not converted
2021-03-16
Now: Outperform